Clinical trials: Sars-CoV-2 Infection
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Bioavailability
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants.
- Trial name
- NCT05263921
- Testing
- PF-07321332/ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program
This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety, tolerability, PK, and PD of single- and multiple-ascending doses of RLS-0071 in healthy adult subjects.
- Trial name
- NCT05298787
- Testing
- RLS-0071
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- ReAlta Life Sciences, Inc.
SARS-CoV-2 Infection
Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing SARS-Cov-2 Viral Load.
A nasal spray based on Advanced Water S-100 ionized water would clean the nasal cavity, reduce the viscosity of the mucus and facilitate its elimination and the decongestion of the nose and the prevention of the seizure of the…
- Trial name
- NCT05290987
- Testing
- nasal spray
- Where
- France
- Volunteers
- 13 people
- Sponsor
- P & B Group
COVID-19, COVID-19 Pandemic
PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
A galectin antagonist prevents viral entry of Sars-CoV-2 virus by blocking the specific terminal on the surface receptors that enables the virus to enter human cells.
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS-CoV2 Infection
- Trial name
- PROTECT (NCT05096052)
- Testing
- Galactomannan
- Volunteers
- 408 people
- Sponsor
- Bioxytran Inc.
SARS-CoV-2
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
- Trial name
- NCT04673149
- Testing
- GLS-5310
- Where
- South Korea
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Acute Respiratory Distress Syndrome
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Recent COVID 19 pandemic has overwhelmed health services all around the world, and humanity has yet to find a cure or a vaccine for the treatment of patients, mainly the severe ones, who pose a therapeutic challenge to healthcare…
- Trial name
- NCT04390152
- Testing
- Wharton's jelly derived Mesenchymal stem cells.
- Where
- 2 sites in Colombia
- Volunteers
- 6 people
- Sponsor
- BioXcellerator
Covid19
Sotrovimab Expanded Access Treatment Protocol (COVID-19)
An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.
- Trial name
- NCT05235347
- Testing
- Sotrovimab
- Where
- 4 sites in United States
- Sponsor
- Vir Biotechnology, Inc.
Covid-19, Protection Against COVID-19
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was skipped due to changes in the overall clinical development plan.
- Trial name
- NCT04537949
- Testing
- BNT162b3
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19
Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.
- Trial name
- NCT04604678
- Testing
- Metformin, Naltrexone
- Where
- United States
- Sponsor
- AgelessRx
Covid19, Corona Virus Infection
SPI-1005 Treatment in Moderate COVID-19 Patients
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19…
- Conditions
- Covid19, Corona Virus Infection, Coronavirus, Coronavirus Infection
- Trial name
- NCT04484025
- Testing
- Ebselen
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Covid19, Long COVID-19
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
- Conditions
- Covid19, Long COVID-19, Post-COVID-19 Syndrome
- Trial name
- NCT04604704
- Testing
- Naltrexone, NAD+
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- AgelessRx
Viral Infection, COVID-19
Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers
The study aimed for: 1. Comparative evaluation of the safety of the drug Molnupiravir, capsules, 200 mg (JSC "Valenta Pharm", Russia), and Lagevrio, capsules, 200 mg (Merck Sharp \& Dohme (UK) Limited, UK), based on the analysis…
- Trial name
- NCT05412173
- Testing
- Molnupiravir
- Where
- Russia
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial. The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral…
- Trial name
- NCT05465902
- Testing
- Recombinant COVID-19 variant Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated, mRNA COVID-19 vaccine (Moderna)
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Major Depressive Disorder, Generalized Anxiety
Scaling Mental Healthcare in COVID-19 With Voice Biomarkers
This study aims to advance research on group sessions for mental health. The first-of-its-kind study measuring various features in a group setting, combining rich metadata in creating state-of-the-art machine learning models, and…
- Trial name
- NCT04510519
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the…
- Trial name
- NCT05142553
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- 10 sites in Spain
- Volunteers
- 887 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study…
- Trial name
- NCT05261139
- Testing
- nirmatrelvir, ritonavir
- Where
- 73 sites in United States, Bulgaria and 5 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
COVID-19
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from…
- Trial name
- NCT04295551
- Testing
- Lopinavir / ritonavir tablets combined with Xiyanping injection, Lopinavir/ritonavir treatment
- Volunteers
- 80 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
COVID-19
Desidustat in the Management of COVID-19 Patients
This study is a Phase 2b, Multicenter, Open-label, Randomized, Comparator- Controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of mild, moderate and severe COVID-19 patients.
- Trial name
- NCT04463602
- Testing
- Desidustat, Standard of Care
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Covid-19 Vaccine
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
This is a Phase II/III, randomized, double-blinded study in adults ≥ 18 years old who received 2 or more doses of inactivated COVID-19 vaccine to evaluate the efficacy, safety and immunogenicity of a booster dose of PIKA COVID-19…
- Trial name
- NCT05463419
- Testing
- PIKA COVID-19 vaccine, Inactivated Covid-19 vaccine
- Where
- 6 sites in Philippines, United Arab Emirates
- Volunteers
- 5,860 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.